Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer using its proprietary enzyme technology platform. The company’s lead drug candidate is Imlifidase, an IgG-degrading enzyme of Streptococcus pyogenes (IdeS), an antibody cleaving enzyme for enabling kidney transplantations in sensitized patients, as well as for anti-GBM antibody disease and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), a cancer immunotherapy. The company also has licensing agreement with Axis-Shield Diagnostics Limited for Heparin Binding Protein (HBP)-assay, a method that predicts severe sepsis in emergency clinics. Hansa Biopharma AB (publ) is headquartered in Lund, Sweden.
Applied LifeSciences & Systems is a bio-systems company focused on improving animal health and productivity in the poultry, livestock, and aquaculture industries. ALS-S is developing a solution that revolutionizes current vaccination methods. Our technology will detect, target, and deliver vaccines to each and every chick, ensuring effective vaccination. This one-of-a-kind accuracy and consistency in the vaccination process boosts the natural immune response to diseases, improves overall flock health, and provides for a cleaner, healthier chick.
Private Equity Round in 2021
Dermavant Sciences is a biotechnology company focused on dermatology.
Private Equity Round in 2021
Argenta is a contract research organization and contract manufacturing organization that specializes in animal health. The company offers a range of services, including pre-clinical development and the manufacturing of veterinary products such as solid dose tablets, topical liquids, sterile injectables, and oral liquids. With facilities located in New Zealand, the United Kingdom, and the United States, Argenta provides comprehensive product development services to clients globally, catering to various scales of production needs.
Private Equity Round in 2021
Aceragen is a developer of therapeutic treatments intended for rare and ultra-rare diseases.
Cerevel (www.cerevel.com) is a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system (CNS). The company has a portfolio of pre-commercial neuroscience assets, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of CNS disorders including Parkinson’s, Alzheimer’s, epilepsy, schizophrenia and addiction. Headquartered in the Greater Boston area, Cerevel was formed in 2018 through a partnership between Bain Capital and Pfizer.
Mileutis LTD is a biopharmaceutical company based in Ness Ziona, Israel, founded in 2004. It focuses on the discovery, development, and commercialization of biologically sourced therapies for both animal and human health. The company's primary offerings include Imilac, an intramammary solution designed for use at the beginning of the dry period, which aids in the management and prevention of bovine mastitis, and Milac, intended for treating intramammary infections during lactation. Mileutis is committed to developing natural and novel peptides that address chronic and infectious diseases, aiming to reduce antibiotic use in both human and animal health sectors while enhancing productivity in veterinary dairy management.
Arvelle Therapeutics GmbH, a biopharmaceutical company, focuses on solutions for patients suffering from CNS disorders. It is involved in the development and commercialization of cenobamate, an investigational antiepileptic drug in the European market. The company was founded in 2019 and is headquartered in Zug, Switzerland.
InformedDNA is a provider of genetics benefits management services that connects genetic counselors to patients, enhancing access to genomic expertise in healthcare. As the nation's largest independent network of genetics specialists, the company offers a comprehensive evidence-based knowledge library focused on genetic tests and hereditary conditions. InformedDNA supports health plans, health systems, and providers by offering services such as policy development, prior authorization for genetic testing and specialty drugs, and utilization analytics. Their approach emphasizes personalized care and informed decision-making, with the goal of optimizing healthcare spending while improving patient outcomes. By facilitating direct access to genetics experts, InformedDNA empowers healthcare providers to utilize cutting-edge genetic insights effectively, ensuring patients receive appropriate testing and care.
Private Equity Round in 2019
Nevakar Inc. is a pharmaceutical company based in Bridgewater, New Jersey, established in 2015. The company specializes in developing innovative ophthalmic and injectable products, aiming to enhance existing FDA-approved molecules to meet unmet clinical and commercial needs. Nevakar's operations are supported by a state-of-the-art research and development infrastructure located in the New Jersey Center of Excellence, coupled with a knowledgeable management and leadership team that guides its intensive research and clinical efforts.
Arvelle Therapeutics GmbH, a biopharmaceutical company, focuses on solutions for patients suffering from CNS disorders. It is involved in the development and commercialization of cenobamate, an investigational antiepileptic drug in the European market. The company was founded in 2019 and is headquartered in Zug, Switzerland.
Private Equity Round in 2018
Roivant’s mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the healthcare system. Roivant does this by building Vants - nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology. In addition to its biopharmaceutical subsidiaries, Roivant also builds technology-focused Vants focused on improving the process of developing and commercializing medicines.
Mesoblast Limited is a biopharmaceutical company that specializes in the development and commercialization of allogeneic cellular medicines, focusing on regenerative medicine. The company utilizes its proprietary Mesenchymal Precursor Cell (MPC) technology to address various significant clinical conditions, including cardiovascular diseases, orthopedic disorders, oncology, inflammatory diseases, and diabetes. Mesoblast's products in Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease, MPC-150-IM for advanced heart failure, and MPC-06-ID for chronic low back pain. Additionally, the company is advancing MPC-300-IV in Phase II trials for biologic refractory rheumatoid arthritis and diabetic kidney diseases. Mesoblast has established strategic partnerships to enhance its product offerings, including collaborations for heart failure treatments in China and chronic pain therapies. Founded in 2004 and headquartered in Melbourne, Australia, Mesoblast operates across several countries, including the United States, Singapore, the United Kingdom, and Switzerland.
Private Equity Round in 2018
Clinical Ink, Inc. specializes in eSource and patient engagement solutions designed to enhance the efficiency of clinical research for sites, sponsors, contract research organizations (CROs), and patients. The company offers a range of products, including SureSource, an electronic source platform that facilitates the electronic capture of data and documents at clinical sites. Additionally, Clinical Ink provides Lunexis ePRO+, a technology that simplifies the implementation process and allows flexibility for patient participation. The CentrosHealth platform further engages patients through configurable applications that ensure they remain informed and compliant throughout clinical trials. Founded in 2006, Clinical Ink is headquartered in Horsham, Pennsylvania, with additional offices in North Carolina, Philadelphia, and Cambridge, Massachusetts. The company maintains a strategic alliance with CogState Limited.
Azurity Pharmaceuticals is a developer of drug products and technologies to address the needs of patients. Its drug products such as antimicrobial, mouthwashes, and testosterone enable pharmacists to prepare drugs for those populations who are in need of a better alternative to traditionally-compounded medications.
Viamet Pharmaceuticals discovers and develops "best-in-class" inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, their Metallophileâ„¢ Technology. Viamet's disruptive Metallophileâ„¢ technology is based on their world-class expertise in bioinorganic chemistry and metalloenzymes and allows them to identify validated targets with high therapeutic and commercial potential; leverage existing metalloenzyme inhibitors as the basis for Viamet's best-in-class analogs; and rapidly and cost-effectively generate best-in-class, patentable, small molecule compounds by optimizing the metal-binding component of existing inhibitors.
Myovant Sciences is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for women's health and endocrine diseases. The company's primary product is relugolix, an oral, once-daily medication that functions as a gonadotropin-releasing hormone receptor antagonist, targeting conditions such as heavy menstrual bleeding associated with uterine fibroids, endometriosis-related pain, and advanced prostate cancer. Additionally, Myovant is advancing MVT-602, an oligopeptide kisspeptin agonist aimed at treating female infertility in assisted reproduction. The company collaborates with Pfizer to enhance the development and commercialization of relugolix in both oncology and women's health. Founded in 2016 and based in London, Myovant Sciences was previously known as Roivant Endocrinology Ltd. and currently operates as a subsidiary of Sumitovant Biopharma Ltd.
PreCision Dermatology is a fully-integrated dermatology company with a mission to deliver innovative therapies to doctors and patients that demonstrably improve the care of skin. PreCision Dermatology is expanding rapidly through internally generated innovation, acquisitions, in-licensing, and co-marketing opportunities.
Revance Therapeutics, Inc. is a biotechnology company focused on the development, manufacture, and commercialization of neuromodulators for aesthetic and therapeutic uses. The company’s lead product, DaxibotulinumtoxinA for injection (DAXI), is undergoing clinical trials for various conditions, including glabellar lines, cervical dystonia, adult upper limb spasticity, and chronic migraine. In addition, DAXI is being evaluated for cosmetic applications such as forehead lines and lateral canthal lines. Revance is also developing DaxibotulinumtoxinA Topical for both therapeutic and aesthetic purposes, and it is working on a biosimilar to BOTOX in collaboration with Mylan. Founded in 1999 and originally known as Essentia Biosystems, the company is headquartered in Newark, California.
Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.
Revance Therapeutics, Inc. is a biotechnology company focused on the development, manufacture, and commercialization of neuromodulators for aesthetic and therapeutic uses. The company’s lead product, DaxibotulinumtoxinA for injection (DAXI), is undergoing clinical trials for various conditions, including glabellar lines, cervical dystonia, adult upper limb spasticity, and chronic migraine. In addition, DAXI is being evaluated for cosmetic applications such as forehead lines and lateral canthal lines. Revance is also developing DaxibotulinumtoxinA Topical for both therapeutic and aesthetic purposes, and it is working on a biosimilar to BOTOX in collaboration with Mylan. Founded in 1999 and originally known as Essentia Biosystems, the company is headquartered in Newark, California.
Private Equity Round in 2011
BioCritica is a biotechnology company focused on meeting the critical care needs of patients and clinicians in the hospital market. In addition to Xigris for the treatment of severe sepsis, BioCritica is developing a pipeline of other products. Their mission is to develop and commercialize products that make a dramatic improvement in people's lives.
Artisan Pharma, Inc., a biopharmaceutical company, provides critical-care and hospital-based therapeutics to patients, treating physicians, and payors in the United States and internationally. It offers ART-123, a novel, recombinant, and soluble thrombomodulin for the treatment of disseminated intravascular coagulation in sepsis. The company offers its products in Japan, China, Taiwan, and Korea. It has a strategic manufacturing alliance with A-Bio Pharma Pte Ltd. Artisan Pharma, Inc. was formerly known as Artisan Therapeutics, Inc. and changed its name to Artisan Pharma, Inc. in September 2006. The company was founded in 2006 and is headquartered in Waltham, Massachusetts.
Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.
Protemix is a biopharmaceutical company that discovers, develops, and commercializes drug therapies for the prevention and treatment of cardiovascular disease, diabetes, and other metabolic disorders. The company was founded in 1999 and is based in Auckland, New Zealand with an additional office in San Diego, California.
Artisan Pharma, Inc., a biopharmaceutical company, provides critical-care and hospital-based therapeutics to patients, treating physicians, and payors in the United States and internationally. It offers ART-123, a novel, recombinant, and soluble thrombomodulin for the treatment of disseminated intravascular coagulation in sepsis. The company offers its products in Japan, China, Taiwan, and Korea. It has a strategic manufacturing alliance with A-Bio Pharma Pte Ltd. Artisan Pharma, Inc. was formerly known as Artisan Therapeutics, Inc. and changed its name to Artisan Pharma, Inc. in September 2006. The company was founded in 2006 and is headquartered in Waltham, Massachusetts.
Sirion Therapeutics is a Tampa, FL-based company dedicated to the development and commercialization of innovative ophthalmic products.